ELUTIA INC.
No SEC Form 4 filings for $ELUT in the last 30 days.
See all $ELUT insider activity →ELUTIA INC. (ELUT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 elut-20260813xex99d1.htm EX-99.1 Exhibit 99.1 Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results Independent Blinded Survey of 50 Plastic Surgeons Validates Demand; NXT-41 and NXT-41x Remain On-Track ● F
ELUTIA INC. (ELUT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 tm2620864d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Execution Version CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (i) NOT MATERIAL AND (ii) THE REGI
Healthcare stocks moved on multiple FDA and EU updates. Novartis (NVS) won FDA approval for Fabhalta in IgA nephropathy; Merck (MRK) got FDA nod for LIPFENDRA and KEYTRUDA+Padcev in bladder cancer; Novo Nordisk (NVO) received EU approval for oral Wegovy. Lilly (LLY) agreed to buy AtaiBeckley for $6.75/share plus up to $2.50 CVR.
Over the past 7 days, alphai's AI scored 1 news story mentioning ELUT (ELUTIA INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ELUT coverage spans financial news, corporate actions and earnings.
Funding runway and FDA milestone expectations are the core near-term drivers for ELUT’s risk profile and valuation path.
The filing discloses a signed, material definitive agreement for an asset sale, which can re-rate ELUT on deal certainty, closing timeline, and contingent consideration risk.
Divestiture refocuses Elutia toward NXT-41x and may reduce complexity, but scale appears small versus broader company value.
The disclosed divestiture terms and non-dilutive funding plan are a near-term balance-sheet catalyst and can re-rate risk around NXT-41x execution.
Share-plan expansion can modestly affect dilution expectations and equity-compensation overhang, but it is not a fundamental operating update.
alphai scores every news story that mentions ELUT with an AI model for sentiment and relevance, and aggregates insider trades from ELUTIA INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ELUTIA INC. (ELUT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 elut-20260813xex99d1.htm EX-99.1 Exhibit 99.1 Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results Independent Blinded Survey of 50 Plastic Surgeons Validates Demand; NXT-41 and NXT-41x Remain On-Track ● F
6 min readELUTIA INC. (ELUT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 tm2620864d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Execution Version CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (i) NOT MATERIAL AND (ii) THE REGI
4 min readHealthcare stocks moved on multiple FDA and EU updates. Novartis (NVS) won FDA approval for Fabhalta in IgA nephropathy; Merck (MRK) got FDA nod for LIPFENDRA and KEYTRUDA+Padcev in bladder cancer; Novo Nordisk (NVO) received EU approval for oral Wegovy. Lilly (LLY) agreed to buy AtaiBeckley for $6.75/share plus up to $2.50 CVR.
7 min readElutia (NASDAQ:ELUT) will sell a legacy business to refocus on its NXT-41x medical technology. The company expects $8 million upfront at closing, plus up to $3 million tied to technology transfer and commercial milestones over 18 months. The deal is expected to close in 2H 2026, with NXT-41x rollout targeted for 2027. Shares were $0.95.
3 min readELUTIA INC. (ELUT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. ELUTIA INC._June 11, 2026 0001708527 false 0001708527 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of
3 min readElutia has announced a $13.26 million registered direct offering, selling 3,175,000 shares of its Class A common stock at $3.40 per share and 725,000 prefunded warrants at $3.399 per warrant. The proceeds will be used for working capital and general corporate purposes. Lake Street Capital Markets is acting as the exclusive placement agent, with the offering expected to close around June 18, 2024.
3 min readThis page provides the latest news and market updates for Elutia Inc. (ELUT), a regenerative medicine company focusing on drug-eluting biomatrix products. It covers recent developments such as compliance with Nasdaq listing requirements, executive appointments, financial results, and progress on their NXT-41 and NXT-41x biomatrix programs for reconstructive surgery. The company aims to leverage asset sale proceeds to fund the development and commercialization of these products.
3 min readIndustry leader brings 40 years of executive and board experience across the global medical technology sector GAITHERSBURG, Md., Oct. 10, 2025 ( GLOBE NEWSWIRE ) -- Elutia Inc. ( NASDAQ:ELUT ) ( "Elutia" or the "Company" ) , a pioneer in drug-eluting biomatrix technologies, announced the ...
3 min readIndustry leader brings 40 years of executive and board experience across the global medical technology sector ...
2 min read- Strengthened balance sheet to fully fund development and launch of NXT-41 platform - - Biologics for breast reconstruction represents $1.5 billion U.S. total addressable market -
4 min read
